INOVIO Provides an Update on Lassa Fever and MERS Programs
PLYMOUTH MEETING, Pa., Nov. 17, 2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prevent infectious diseases, cancer, and diseases associated with HPV, today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Infectious Diseases | Lassa Fever | MERS | Pharmaceuticals